Jian Huang

6PUBLICATIONS
27CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursHaematologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 17, 2026
Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Fang Cheng, Yu Wang, Yunfan Yang

|Oct 08, 2025
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

Jian Huang, Rumeng Li, Tiejun Gong

|Jan 15, 2025
α-Actinin-1 deficiency in megakaryocytes causes low platelet count, platelet dysfunction, and mitochondrial impairment.

Xiangjie Lin, Hanchen Gao, Min Xin

|Nov 22, 2024
Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model.

Tian Zeng, Xiudi Yang, Yi Wang

|Jul 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang

|Dec 11, 2022
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study.

Shiwei Hu, Dan Chen, Xiaofei Xu

Pageof 1

Frequent Collaborators

2 joint publications

Qian Jiang

2 joint publications

Jie Jin

1 joint publications

Xiaofei Xu

1 joint publications

Robert Peter Gale